AbbVie will test lutikizumab together with ABBV-295, the amylin-based obesity drug it licensed from Danish biotech Gubra, ...

China has more house dust mite allergy sufferers than any other country, but fewer than 1 million of an estimated 100 million ...

All major hearing aid makers are launching new premium devices at the same time, but Søren Nielsen expects audiologists to ...

EU panel backs Eli Lilly’s Foundayo obesity pill Eli Lilly is still awaiting final approval from the European Commission.

Lundbeck's product development lead has passed away Lars Bang spent his entire professional career at Lundbeck and was a member of the company’s senior management team.

Former GN executive to lead Nordic expansion of AI cell-therapy company that took over Novo program Peter Aksel Villadsen leaves GN after six years to build up Cellular Intelligence in the Nordics, as ...

US pharma lobby group names new chief executive Former Republican Majority Leader Eric Cantor is set to take the helm at PhRMA following Steve Ubl’s who har served more than ten years in the position.

Novo Nordisk's Ozempic shows lower risk of major cardiovascular events New registry data point to a difference in the risk of major cardiovascular events. The study stresses, however, that the results ...

Zealand Pharma shares fell nearly 11% after a second phase 3 study showed many patients dropping out. Partner Boehringer Ingelheim blames the dropouts on limited dosing flexibility. Data suggests that ...